SEC Filing | Rocket Pharmaceuticals, Inc.

View:

Download DOC

Download PDF

Download XLS

Download XBRL

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2023

Rocket Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36829	04-3475813
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9 Cedarbrook Drive, Cranbury, NJ		08512
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (646) 440-9100

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.01 par value		RCKT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

Attached as Exhibit 99.l to this Current Report on Form 8-K, and incorporated into this Item 7.01 by reference, is an investor presentation (the “Investor Presentation”) prepared by Rocket Pharmaceuticals, Inc. (the “Company”) providing certain updates on the Company’s Danon Disease Program, including the alignment it recently achieved with the Food and Drug Administration (FDA) on the design of the Phase 2 pivotal trial of RP-A501 for Danon Disease.

The information in this Item 7.01, including Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained in this Item 7.01, including Exhibit 99.1.

Item 8.01.

Other Events.

On September 12, 2023, the Company issued a press release announcing that alignment has been reached with the FDA on the design of the Phase 2 pivotal trial of RP-A501 for Danon Disease. A copy of the press release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.	Description
99.1	Investor Presentation dated September 11, 2023.
99.2	Press Release dated September 12, 2023.
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 12, 2023	Rocket Pharmaceuticals, Inc.

	By:	/s/ Gaurav Shah, MD
	Name:	Gaurav Shah, MD
	Title:	Chief Executive Officer and Director

Exhibit 99.1

S E E K I N G G E N E T H E R A P Y C U R E S Rocket Pharmaceuticals Danon Disease Program Update September 11, 2023 1 CONFIDENTIAL AND PROPRIETARY

Disclaimer 1 CONFIDENTIAL AND PROPRIETARY Various statements in this presentation concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Danon Disease (DD), the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, Rocket’s plans for the advancement of its Danon Disease program, including its planned pivotal trial, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, our ability to submit regulatory filings with the U.S. Food and Drug Administration (FDA) and to obtain and maintain FDA or other regulatory authority approval of our product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, our competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, our integration of an acquired business, which involves a number of risks, including the possibility that the integration process could result in the loss of key employees, the disruption of our ongoing business, or inconsistencies in standards, controls, procedures, or policies, our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire and any unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 28, 2023 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Danon Disease Aggressive genetic hypertrophic cardiomyopathy with very high early mortality Danon Disease is the most aggressive and lethal hypertrophic cardiomyopathy Monogenic, X-linked disease progresses to severe cardiomyopathy at early ages; characterized by massive LV hypertrophy and end-stage heart failure Uniformly fatal with early mortality (males ~19 yrs.; females ~37 yrs.) Only definitive treatment is cardiac transplantation, availability is limited, and associated with extensive short- and long-term morbidity and mortality (<50% 10-yr survival post HTx) Estimated prevalence of 15,000 to 30,000 individuals and annual incidence of 800 to 1,200 individuals in US & EU In July 2023, US Dept. Health and Human Services approved IDC 10 Code for DD (E74.05) Gene mutation leads to decreased LAMP2B protein and impaired autophagy Cenacchi G et al. Neuropathol. Appl. Neurobiol. 2020; Rowland T et al. J Cell Sci. 2016; Boucek D, Jirikowic J, Taylor M. Genet Med 2011; Thrush P et al. J Thorac Dis. 2014; Dipchand A et al. J Heart Lung Transplant. 2014 Impaired autophagy leads to ↑ vacuoles, myocyte hypertrophy, necrosis, & fibrosis 1 2 3 Pathologic processes lead to phenotype of extreme LV hypertrophy and cardiomyopathy 4 Natural History: High rates of death at early ages Females Males 3 3 CONFIDENTIAL AND PROPRIETARY

Natural History: Progression of Danon Disease in Male Patients Birth to 7 yrs NYHA Class I Muscle pain, lack of energy Learning difficulties HF symptoms (rare) Identification by incidental genetic testing or family history Death avg age: 19 years 8-14 yrs NYHA Class I-II HCM & genetic diagnosis Worsening fatigue, Shortness of breath on mild exercise Palpitations, syncope, chest tightness Thickening heart, increasing NPs, troponins 15-19 yrs NYHA Class II-III Life-threatening ventricular arrhythmias ICD/pacemaker placement Progression to end-stage cardiomyopathy Listing for heart transplant Significant increase in caregiver burden Thickening heart, increasing NPs, troponins, fibrosis; decline in LVEF Late Teens / Early Twenties Significant cardiac dysfunction Heart failure Heart transplant / VAD (~20% of patients), comes with significant short- and long- term complications Anxiety, depression Unemployment Figure created based on data from Brambatti M et al. Int J Cardiol. 2019;286:92-98; Boucek D, Jirikowic J, Taylor M. Genet Med 2011; 13(6):563-68 CONFIDENTIAL AND PROPRIETARY 4 Critical interval in childhood / early adolescence precedes rapid decline, providing optimal window of opportunity for GTx Patients typically on maximal medical management (e.g. beta blockers, ICD) - none alter disease progression Note: Danon disease is a life-threatening and seriously debilitating condition. Above are not meant to be a strict categorization of symptoms/outcomes by age. Heart failure and death from Danon disease can occur well before the patient reaches his twenties. Of note, the four adult patients in the Phase 1 study with 2.5-3.5 yr follow-up post gene therapy are currently alive, clinically stable, and free from Danon disease progression at ages 21-24 years old – in contrast to the trend in the natural history of this disease. NYHA = New York Heart Association Class; ICD: implantable cardioverter-defibrillator; HTx = Heart Transplantation; VAD: Ventricular Assist Device

Phase 1 Data: Benefit Observed Across All Key Clinical Parameters Early LAMP2, BNP, TnI changes associated with sustained clinical improvement and guided Phase 2 endpoint selection Does not include pt 1007 in Ph1 trial who had advanced HF with EF<40% at enrollment and received HTx 5M following tx due to pre-existing advanced HF. Patient is currently stable. BNP, brain natriuretic peptide; hsTnI, high- sensitivity troponin I; KCCQ, Kansas City Cardiomyopathy Questionnaire; LAMP2, lysosome-associated membrane protein 2; LV, left ventricle; NYHA, New York Heart Association. Data cut-off Oct 6, 2022; Grade 0=negative All specified parameters either improved or stabilized (none deteriorated) Improved Stabilized Worsened 5 CONFIDENTIAL AND PROPRIETARY staining; Grade 1 ≤25%; Grade 2 =26%-50%; Grade 3 =51%-75%; Grade 4 >75%. Low dose = 6.7x1013 GC/kg, high dose = 1.1x1014 GC/kg CONFIDENTIAL AND PROPRIETARY 5 Cohort Patient ID Follow-up (months) Myocardial LAMP2 Grade (≤M12) TnI Δ (≤M12) BNP Δ (≤M12) LV mass Δ (g) LV Mass Index Δ (g/m^2.7) Max LV Wall Thickness Δ (mm) NYHA class Δ KCCQ score Δ Low dose adult/ adolescent 1001 36 1 -75% (M18) -36% 311 ⇢ 212 85 ⇢ 57 25 ⇢ 23 II ⇢ II 44 ⇢ 49 1002 36 3 -79% -76% 989 ⇢ 511 260 ⇢ 129 64 ⇢ 38 II ⇢ II 64 ⇢ 81 1005 30 2 (M9) -57% (M9) -64% (M9) 438 ⇢ 375 98 ⇢ 76 33 ⇢ 24 II ⇢ I 77 ⇢ 85 (M24) High dose adult/ adolescent 1006 24 1 -47% -70% 410 ⇢ 300 90 ⇢ 63 22 ⇢ 18 II ⇢ I 79 ⇢ 82 Low dose pediatric 1008 12 1 -86% -83% 605 ⇢ 447 140 ⇢ 96 42 ⇢ 39 II ⇢ I 50 ⇢ 82 1009 6 1 -90% -62% 234 ⇢ 185 83 ⇢ 63 20 ⇢ 20 II ⇢ I 52 ⇢ 78

Latest Pediatric Data Shows Sustained Improvements in Biomarkers, Symptoms, and Function (Updated Data) Variable Baseline2 Most Recent Follow-up LAMP2 protein3 0 1 (M6) Troponin-I (ng/mL) 0.67 0.08 (-88%) BNP (pg/mL) 297 163 (-45%) NYHA Class II I LV Mass Index 83 60 (-28%)4 12 months AGE AT INFUSION 11.7 years ICD no WPW no Subject ID: A501-008-1008 Baseline Characteristics AGE AT INFUSION 12.3 years ICD yes1 WPW yes Variable Baseline2 Most Recent Follow-up LAMP2 protein3 0 1 (M12) Troponin-I (ng/mL) 1.89 0.30 (-84%) BNP (pg/mL) 1837 328 (-82%) NYHA Class II I LV Mass Index 140 96 (-31%)4 18 months MAX LV WALL THICKNESS 41.9 mm, z-score +32 6MWT 438 meters MAX LV WALL THICKNESS 19.8 mm, z-score +12 6MWT 553 meters Subject ID: A501-008-1009 Baseline Characteristics 1 Recommended prior to enrollment; ICD implanted 3 months after RP-A501 infusion. 2 Baseline values for troponin-I and BNP are the mean values from all pre-dose visits. 3 Extent of LAMP2 expression grading: Grade 0 = negative staining, Grade 1 < 25%, Grade 2 = 26-50%, Grade 3 = 51-75%, Grade 4 > 75%. 4M12 Note: All data preliminary, not yet validated. 6MWT, 6-minute walk test; BNP, brain natriuretic peptide; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City cardiomyopathy questionnaire; LAMP2, lysosome-associated membrane protein 2; LV, left ventricle; NYHA, New York Heart Association; WPW, Wolff-Parkinson-White syndrome. 6 6 CONFIDENTIAL AND PROPRIETARY `

Pivotal, single-arm study Peds safety run-in Dosage (6.7x1013 GC/kg) Safety protocol & management plan CMC (product comparability and potency assay) NHS to serve as external comparator RMAT designation granted F2F meeting with review team and senior FDA leadership Co-primary endpoint to support accelerated approval consisting of LAMP2 expression & LV Mass reduction of ≥ 10% N=12 patients for pivotal study with potential for primary endpoint readout at 12 months Study to support AA with a path towards conversion to full approval (with longer follow-up) FDA Engagement and Alignment on Danon Program Since the EOP1 Meeting in November 2022, Rocket has had collaborative formal and informal discussions with FDA to align on the optimal pivotal Phase 2 study design Previously Disclosed Trial Elements Recent Engagement and Alignment 8 CONFIDENTIAL AND PROPRIETARY

Phase 2 Trial Design – 12 Patients with 12-month Primary Endpoint Duration Dose: 6.7 x 1013 GC/kg of commercially representative RP-A501 material Initial n=2 peds followed for 90 days for key AAV-associated toxicities prior to subsequent ped pt enrollment Key eligibility criteria: male age ≥8y, LAMP2 mutation, NYHA II-III, evidence of LV hypertrophy, elevated hsTnI CO-PRIMARY ENDPOINT (AA) LAMP2 protein ≥ Grade 1 (IHC) AND Left Ventricular Mass (LV Mass): ≥10% ↓ SECONDARY & EXPLORATORY ENDPOINTS hs-troponin I (key secondary) Natriuretic peptides QoL instruments (KCCQ, PedsQL, PGI-C, PGI-S) NYHA Class 6MWT Event free survival Treatment emergent safety events Actigraphy Tx, treatment; LV, left ventricular; NYHA; IDSMC, Independent Data Safety and Monitoring Committee; hs-troponin I; KCCQ; HF; m, month; y, year; pts, patients Adolescent/Adult Cohort ≥15y End of Study 60m Primary Endpoint Assessment ~12m RISK MANAGEMENT PLAN, TRIAL OVERSIGHT Immunomodulatory regimen of Rituximab, Sirolimus, corticosteroids. Clinical monitoring team to closely monitor labs, clinical sequelae for AAV-associated toxicities. IDSMC: expertise in adult and pediatric cardiomyopathy, immunology, and biostatistics RP-A501 Tx CONCURRENT NATURAL HISTORY STUDY 90d (Additional pediatric dosing following Safety Run-in) Pediatric (8-14y) Safety Run-in (n=2) RP-A501 Tx Peds pt #1 Peds pt #2 1m Safety observation Pivotal, global, single-arm, open label study with external comparator PIVOTAL PHASE 2 STUDY DESIGN 8 CONFIDENTIAL AND PROPRIETARY

9 HTx, heart transplant; LVEF, LVEF, left ventricle ejection fraction. US Retrospective Natural History 9 Males 1 Female 51 Males 21 Males 38 Females Initiated in 2019, study complete Initiated in 2006 Enrollment complete; analysis in Q4 2023 67 Females Prospective Natural History Study EU Retrospective Natural History Study To be expanded through an additional prospective Rocket-initiated natural history study Key Elements of Study Design: Entry criteria and endpoints similar to Phase 2 trial Appropriate matching to ensure robust comparisons Retrospective data collection to supplement prospective evaluation to ensure sufficient comparative data Prospective, Retrospective Natural History Study as External Comparator Allows for robust comparisons and aligned with FDA guidance 9 CONFIDENTIAL AND PROPRIETARY CONFIDENTIAL AND PROPRIETARY

10 Transplant-free survival Totality of Evidence to Demonstrate Treatment Effect Baseline 12 Months 18 Months 24 Months Beyond 24-36 Months HF Hospitalizations Heart Transplant Death Phase 2 RP-A501 Treated Patients External Comparator Natural History (Untreated Patients) Each patient’s baseline AND matched external comparator arm together provide robust control data to assess treatment effect Improvement or stabilization of parameter Worsening of parameter Clinical Assessments Outcomes (Late Δ) Imaging & Biomarkers (Early Δ) (Intermediate Δ) External comparator arm serves as control at each timepoint CONFIDENTIAL AND PROPRIETARY Note: Illustrative representation of potential treatment effects versus natural history

Co-Primary Endpoints for Accelerated Approval 11 CONFIDENTIAL AND PROPRIETARY CONFIDENTIAL AND PROPRIETARY

12 Primary Endpoint Is Reasonably Likely to Predict Clinical Benefit Justification for use of LAMP2 protein expression and LV Mass Mutation of LAMP2 is root cause of Danon disease Epidemiologic support: even modest levels of LAMP2 confer a 2-decade survival advantage in female patients RP-A501 delivers full coding sequence of WT LAMP2 gene Pre-clinical LAMP2 restoration conferred histologic, functional and survival benefits in LAMP2 knock-out model1 Phase 1: LAMP2 expression associated with decreased vacuolar area, improved myofibrillar disarray, clinical improvement WT Full Length LAMP2 Protein Expression Left Ventricular Mass Largest known hearts are Danon disease hearts Severity of the cardiomyopathy in Danon disease is the major prognostic factor2 Retrospective natural history shows year-over-year increases in LV mass in Danon disease patients Phase 1: Consistent and significant reductions in LV mass as early as 6 months by echocardiography and cardiac MRI Primary Endpoint Will Be Interpreted in a Clinical Context: All components are measurable and unlikely to improve in the absence of a true treatment effect Primary endpoint will be assessed in the context of biomarkers, symptoms, QOL, clinical events derived from secondary endpoints and concurrent natural history study Phase 1 trial: LAMP2 expression and LV Mass improvements seen as early as 6 months in pediatric subjects with updated immunomodulation regimen 1 Manso 2020. Sci Transl Med.; 2D’souza 2017. J Community Hosp Intern Med Perspect. CONFIDENTIAL AND PROPRIETARY

Mechanistic Pathway: Protein Expression to Cardiac Structure to Clinical Outcomes Improvements Across Cellular, Cardiac Imaging and Functional Measures in Phase 1 Study Molecular Expression Cellular Structure Cardiac Structure and Function Clinical Status Endomyocardial Bx: LAMP2 protein expression Endomyocardial Bx: Vacuolar area Imaging & Biomarkers: LV Mass, Wall thickness, LVEF Troponin-I, BNP Functional parameters: NYHA Class KCCQ Overall Score Patient Screening Month 3 Month 6 Month 24 Month 36 Predose (Baseline) RP-A501 Note: BNP, brain natriuretic peptide; Bx, biopsy; KCCQ, Kansas City cardiomyopathy questionnaire; LAMP2, lysosome-associated membrane protein 2; LV, left ventricle; LVEF, LV ejection fraction; LVPWd, LV posterior wall end diastole; MLVWT, maximal LV wall thickness; NYHA, New York Heart Association LAMP2 expression and LV Mass are mechanistically linked to functional measures and clinical outcomes; reasonably likely to predict clinical benefit Month 9 Month 12 Month 18 Post Gene Therapy 1 2 3 4 13 13 CONFIDENTIAL AND PROPRIETARY

LAMP2 mutation and associated protein deficit is the root cause of Danon disease pathology Grade ≥1 LAMP2 correlates with evidence of efficacy in Ph1 Absent expression at baseline (Grade 0) in all male patients Improved cardiac biomarkers & hypertrophy, PRO/QOL and NYHA Class – sustained to 3+ years in adult patients, and 12+ months in pediatric patients Efficacy consistent in patients with Grade 1 vs. Grade >1 LAMP2 expression Ph1 expression correlates with ↓ autophagic vacuoles and improved myofibrillar disarray, cardiac biomarkers and hypertrophy In Danon females, partial LAMP2 expression associated with ~2 decade longer survival than males LAMP2 Protein Expression as Co-Primary Endpoint RP-A501 encodes full-length, wild-type LAMP2B; cardiomyocytes are non-dividing cells 14 CONFIDENTIAL AND PROPRIETARY

Rocket AHA 2022 Poster Presentation reflects September 27, 2022 data cutoff. LAMP2, lysosome associated membrane protein 2; M, month. IHC = immunohistochemistry RP-A501 Increases LAMP2 Protein and Decreases Vacuolization Enhanced autophagy leads to improved myocardial ultrastructure and clinical phenotype Myocardial LAMP2 Protein Expression Endomyocardial Biopsy Images (Subject 1008, RP-A501 Phase 1 Study) Vacuolar Area of Endomyocardial Tissue 15 CONFIDENTIAL AND PROPRIETARY 15 CONFIDENTIAL AND PROPRIETARY

Left Ventricle Mass as Co-Primary Endpoint Danon Disease is fundamentally a disease of enlarged hearts; the largest known hearts have been from Danon patients Left ventricular hypertrophy is the most consistent phenotypic feature of disease progression Left ventricular wall thickness has been shown to be a significant predictor of CV events in cardiomyopathy Meaningful LV Mass decreases seen as early as 6-9M in Phase 1 pediatric cohort, and LV Mass Index decreases sustained to up to 36M in adult patients; stark contrast to natural history In Phase 1 study, LV Mass significantly correlated with improvements / stabilization in all parameters including biomarkers (hsTnI, BNP), quality of life (KCCQ), and symptoms (NYHA) 17 CONFIDENTIAL AND PROPRIETARY

LVH Predicts Clinical Outcomes in HF and Cardiomyopathies 17 CONFIDENTIAL AND PROPRIETARY Shah A, JACC 2019; de Simone G. Eur Heart J. 2008; Liu, Q, Scientific Reports, 2016; Orsborne C, JACC, 2022; Hanneman K. Radiology. 2020 Cardiomyopathy or CVD Measure of LVH Event HR; CI; p value HFpEF (Shah 2019) LV Mass index CVD or HFH HR 1.05 per 10 g/m(2); CI 1.00 to 1.10; p = 0.03 HFpEF (de Simone 2008) LV Mass index HF HR 1.03; CI 1.02-1.04; p<0.00001 HCM (Liu 2016) LV wall thickness All Cause Death HR 1.48; CI 1.01 to 2.17; p<0.05 HCM (Liu 2016) LV wall thickness CV Death HR 2.17; CI 1.06 to 1.89; p<0.05 HCM (Liu 2016) LV wall thickness Sudden Cardiac Death HR 3.17; CI 1.64 to 6.13; p<0.05 Fabry Disease (Orsborne 2022) LV Mass index Composite of CV events (HFH, MI, procedures, arrhythmias) HR 1.008; CI 1.003-1.014; p=0.005 Fabry Disease (Hanneman 2020) LV Mass index Composite of CV events (HF, ventricular arrhythmia, cardiac death) HR 1.1 per 5 g/m2; CI 1.04-1.2; p<0.001

LV Mass Index in RP-A501 Phase 1 Study RP-A501 Phase 1 Low-Dose Cohort: LV Mass Index % Change from Baseline1 Baseline 6M 9M 12M 18M 24M 30M -55% -50% -45% -40% -35% -30% -25% -20% -15% -10% -5% 0% 36M 1002 1005 1008 1009 1 Does not include patient 1001 (unmonitored immunomodulation). 212M visit data missing for 1002 and 1005 due to pandemic-related travel issues. CONFIDENTIAL AND PROPRIETARY 18 RP-A501 Phase 1 Study: LV Mass Index % CFB at ~12M (9M or 18M where 12M not available)2 18M 9M 12M 12M -15% -14% -32% -27% 1002 1005 1008 1009 >20% LVMI decrease observed as early as 6M in pediatric cohort, sustained to 12M timepoint Adult patients with appropriate immunomodulation show >10% LVMI decrease around 12M2 with further decreases out to 30-36M of 22% to 51%

Fabry Disease (Agalsidase alfa) LV Mass @6M 8.8% -4.1% Clinical Correlation: Improvements in LVM out to 36M correlated with HF symptoms (NYHA, CCS); drug approved in EU Amyloid Cardiomyopathy (Patirisan) LV Mass @18M <1% -5.6% Clinical Correlation: Drug approved based on improved CV outcomes @30M Significant improvements in 6MWD & NT-proBNP HCM (Mavacamten) LVMI @7M -1.7% -17% Clinical Correlation: ↑ exercise tolerance at 30 weeks NYHA Class ↓ by 1 in 76% treated patients at 120wks Danon Disease1 (RP-A501 Low-dose cohort) 8% LVMI LVMI @9-18M3 @30-36M4 Est. LVM Increase per NxHx2 -22% -36% Clinical Correlation: NYHA Class improvement, KCCQ ↑, improvement or stabilization in hsTnI and natriuretic peptides all to most recent timepoint (12-36M) LV Mass / LV Mass Index (LVMI) Improves in DD with RP-A501 LV hypertrophy decreases greater than/comparable to other approved therapies Placebo / Untreated Estimate from retrospective NxHx Data Treated 1 RP-A501 Phase 1 low-dose cohort data; averages do not include 1001 (unmonitored immunomodulation) and 1006, 1007 (high dose patients). 2 Reflects estimated LV Mass increase over 12-18M for DD patients based on retrospective natural history data-set (shown on slide 20). 3 Reflects average of 1002 18M, 1005 9M, 1008 12M, 1009 12M. 4 Reflects average of 1005 30M, 1002 36M Hughes 2008. Heart; Solomon 2019. Circulation; Saberi 2021. Circulation 19 CONFIDENTIAL AND PROPRIETARY

LV Mass in RP-A501 Low-Dose Cohort Versus Recently Approved CV Therapies -30% -20% -10% 0% 10% Baseline ≤18M DD RP-A501 Tx1 (9-18M); -22% DD RP-A501 Tx1 (30-36M); -36% 30-36M Fabry – Agalsidase Alfa Untreated (6M); +9% DD UnTx @12M (Estimated based on Retro NxHx2); +8% Amyloidosis – Tafamidis Treated (9M); -3.6% HCM - Mavacamten Untreated (7M); -1.7% Amyloidosis – Patisiran Untreated (18M); +1% Amyloidosis – Tafamidis Untreated (9M); +8.1% Fabry – Agalsidase Alfa Treated (6M); -4% Amyloidosis – Patisiran Treated (18M); -5.6% HCM - Mavacamten Treated (7M); -17% Data from Phase 1 study shows RP-A501 is potentially transformative for cardiac structure improvements and remodeling On par with recently approved therapies in other CV indications (across different disease etiologies and drug MOA's) Hughes 2008. Heart; Rettl 2022. EHJ CV Imaging; Solomon 2019. Circulation; Saberi 2021. Circulation CONFIDENTIAL AND PROPRIETARY 20 LV Mass / LVMI Change from Baseline in Treated vs Untreated Patients: RP-A501 Low-Dose Cohort1 and Recently Approved CV Therapies -40% 1 Averages do not include patient 1001 (unmonitored immunomodulation) and 1006, 1007 (high-dose cohort patients). 2 Reflects estimated LV Mass increase over 12-18M for DD patients based on retrospective natural history data-set (shown on slide 20).

* Unpublished data from International Danon Disease Registry 21 Cardiac Imaging Captures the Progression of Danon Disease Significant Increases in LV Mass and LV Wall Thickness Correlate with Age Trends in LV Mass LV Mass increased by 39.86 ± 4.01 g per year Left ventricular mass [g] r2= 0.846 Age (years) Age (years) Interventricular Septum (IVSd) [mm] Age [years] Trends in Septal Wall Thickness Septal wall increased by 0.96 ± 0.10 mm/year 21 CONFIDENTIAL AND PROPRIETARY CONFIDENTIAL AND PROPRIETARY Data from the Natural History Studies demonstrated increases in key echo parameters in DD that are known to predict disease progression in other types of cardiomyopathy n=33 n=22

Note: Upper limit of normal 0.04 ng/mL, BL = baseline 22 Significant and Sustained Reduction in Troponin (Key Secondary Endpoint) Observed Across Patients in Phase 1 Study Phase 1 Trial: RP-A501 Treatment Conferred Improvement in Troponin-I Levels (ng/mL) 2.00 1.80 1.60 1.40 1.20 1.00 0.80 0.60 0.40 0.20 0.00 BL M12 M18 M24 M30 M36 1001 1002 1005 1006 1008 Normal Range 22 CONFIDENTIAL AND PROPRIETARY CONFIDENTIAL AND PROPRIETARY

Current Status and Next Steps 22 CONFIDENTIAL AND PROPRIETARY CONFIDENTIAL AND PROPRIETARY

Ongoing Danon Global Phase 2 Study Activities RMAT, Fast Track, Orphan Drug Designations IRB approval at UCSD, CHOP; sites activated Multiple GMP lots manufactured in-house; sufficient drug product produced for full pivotal trial Global natural history study underway FDA alignment on design Initiated pediatric safety run-in United States Europe (UK + EU) Key regulatory designations obtained: PRIME Designation Orphan Drug Designation Advanced Therapy Medicinal Product Scientific Advice Meeting held with EMA On track for CTA/IMPD filing Multiple EU clinical site startup activities underway Successful QP audit of Rocket manufacturing facility; drug product cleared for EU use Global Phase 2 Study (N=12) 24 CONFIDENTIAL AND PROPRIETARY 25 CONFIDENTIAL AND PROPRIETARY

Rocket Pipeline: 6 Disclosed Programs Across Two Platforms with Compelling Clinical and/or Pre-clinical Proof of Concept On-target MOA; clear endpoints Sizeable market to maximize patient impact First-, best- and/or only-in- class Criteria used to 6+ programs with 2 programs fast approaching commercialization select programs Wave 2 programs DISCOVERY PRECLINICAL PHASE 1 PHASE 2 (Pivotal) Submission and Approval DESIGNATIONS AAV RP-A501 Danon Disease LV RP-L102 Fanconi Anemia LV RP-L201 Leukocyte Adhesion Deficiency-I LV RP-L301 Pyruvate Kinase Deficiency Multiple Undisclosed Candidates AAV BAG3-DCM THERAPEUTIC AREA AAV RP-A601 PKP2-ACM CARDIOVASCULAR HEMATOLOGY RMAT, ATMP, Fast Track, Rare Pediatric, Orphan Drug (US/EU), PRIME RMAT, ATMP, Fast Track, Rare Pediatric, Orphan Drug (US/EU), PRIME RMAT, Fast Track, Orphan Drug (US/EU), PRIME RMAT, Fast Track, Orphan Drug (US), Rare Pediatric Designation, PRIME Fast Track, Orphan Drug (US) 24 CONFIDENTIAL AND PROPRIETARY 25 CONFIDENTIAL AND PROPRIETARY AAV, adeno-associated virus; ATMP, advanced therapy medicinal product; BLA, Biologics License Application; LV, lentiviral vector; MAA, Marketing Authorisation Application; MOA, mechanism of action; PRIME, PRIority MEdicines; RMAT, regenerative medicine advanced therapy. PKP2: plakophilin 2; ACM: Arrhythmogenic Cardiomyopathy; BAG3: BLC2-associated athanogene 3 DCM: Dilated Cardiomyopathy

Exhibit 99.2

Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design in RP-A501 in Danon Disease

Final alignment reached on a single arm, open-label study with natural history comparator and a biomarker based co-primary endpoint consisting of LAMP2 protein expression and Left Ventricular (LV) Mass

12 patient study with primary endpoint assessment at 12 months to support accelerated approval

CRANBURY, N.J. – September 12, 2023 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that alignment has been reached with the Food and Drug Administration (FDA) on the global Phase 2 pivotal trial of RP-A501 for Danon Disease. Danon Disease is a uniformly fatal inherited cardiomyopathy that leads to mortality in the majority of male patients at age ~20 and females at age ~40, and for which there are no approved curative or disease-modifying therapies. The disease affects an estimated 15,000 to 30,000 patients in the U.S. and Europe.

“I am thrilled to announce our alignment with the FDA on the pivotal study design for RP-A501, which reflects the collaborative discussions with the review team and senior management at FDA’s Center for Biologics Evaluation and Research and marks the first-ever regulatory pathway to approval for a genetic treatment for heart disease. We believe this milestone sets us on the most efficient and rapid path to delivering this potentially transformative therapy to Danon Disease patients who would otherwise progress to heart transplantation or death,” said Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma. “I would also like to highlight the work conducted by our CMC team over the past several years to establish our in-house cGMP manufacturing capabilities, which has already provided us with sufficient material for the pivotal study and should support our eventual commercialization efforts.”

Dr. Shah continued “As a one-time potentially curative infusion, RP-A501 has the potential to restore normal cardiac function and provide a lifetime of benefit to patients with Danon Disease who have no other viable treatment options. With today’s progress in our Danon Disease program we believe we are forging a path to bring curative gene therapies to patients affected by devastating cardiovascular diseases and broadening the possibilities for addressing a larger array of inherited heart diseases through the promise of cardiac gene therapy.”

Phase 2 Pivotal Trial of RP-A501 for Danon Disease

The global, single-arm, multi-center Phase 2 pivotal trial will evaluate the efficacy and safety of RP-A501 in 12 patients with Danon Disease, including a pediatric safety run-in (n=2), with a natural history comparator and a dose level of 6.7 x 10¹³ GC/kg.

•	To support accelerated approval, the study will assess the efficacy of RP-A501 as measured by the biomarker-based co-primary endpoint consisting of improvements in LAMP2 protein expression (≥ Grade 1, as measured by immunohistochemistry), and reductions in left ventricular (LV) mass.

•

Key secondary endpoints is change in troponin. Additional secondary endpoints will include natriuretic peptides, Kansas City Cardiomyopathy Questionnaire (KCCQ), New York Heart Association (NYHA) class, event free survival to 24 months and treatment emergent safety events. These endpoints could support a full approval with longer-term follow-up.

•	A global natural history study will serve as an external comparator and run concurrently to the Phase 2 pivotal trial.

•	In-house manufacturing has been completed with sufficient high-quality drug product produced to fully supply the Phase 2 pivotal study. Potency assays have been developed and qualified in accordance with FDA guidance.

Filing of the Clinical Trial Application (CTA)/Investigational Medicinal Product Dossier (IMPD) for RP-A501 to enable initiation of EU study activities is anticipated by the end of the third quarter of this year. Additionally, Rocket has secured an ICD-10 code from CMS for LAMP2 deficiency in Danon Disease.

About RP-A501

RP-A501 is Rocket’s investigational gene therapy product for the treatment of Danon Disease and the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies. Danon Disease is caused by mutations in the LAMP2 gene. RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a full-length, wild-type version of the human LAMP2B transgene (AAV9.LAMP2B) which, when inserted into heart cells harboring mutations in the endogenous LAMP2B gene, has the potential to fully restore cardiac function at its root. RP-A501 represents a single dose treatment and is administered as an intravenous (IV) infusion. In preclinical and clinical studies, AAV9.LAMP2B has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which ultimately leads to improved cardiac structure and function in patients.

About Danon Disease

Danon Disease is a rare X-linked inherited disorder caused by mutations in the gene encoding lysosome-associated membrane protein 2 (LAMP-2), an important mediator of autophagy. This results in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to heart failure, and for male patients, frequent death during adolescence or early adulthood. It is estimated to have a prevalence of 15,000 to 30,000 patients in the U.S. and Europe. The only available treatment option for Danon Disease is cardiac transplantation, which is associated with substantial complications and is not considered curative. There is a high unmet medical need for patients with Danon Disease.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also has received IND clearance for the AAV-based gene therapy program for PKP2-arrhythmogenic cardiomyopathy (ACM) and is advancing a preclinical program for BAG3-associated dilated cardiomyopathy (DCM). For more information about Rocket, please visit www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Danon Disease (DD), the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, Rocket’s plans for the advancement of its Danon Disease program, including its planned pivotal trial, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, our ability to submit regulatory filings with the U.S. Food and Drug Administration (FDA) and to obtain and maintain FDA or other regulatory authority approval of our product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, our competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, our integration of an acquired business, which involves a number of risks, including the possibility that the integration process could result in the loss of key employees, the disruption of our ongoing business, or inconsistencies in standards, controls, procedures, or policies, our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire and any unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 28, 2023 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Media

Kevin Giordano

kgiordano@rocketpharma.com

Investors

Brooks Rahmer

investors@rocketpharma.com